Drug-induced cardiovascular adverse events remain a leading factor behind drug withdrawals from the market and drug label restrictions. Early identification of a drug candidate’s potential to induce arrhythmias is therefore critical in the drug development process. Certara’s Cardiac Safety Simulator (CSS) offers a sophisticated solution to this challenge.
This state-of-the-art modeling and simulation platform is specifically designed to evaluate the pro-arrhythmic potential of drugs, new chemical entities, and other xenobiotics within the intended clinical population, providing a proactive approach to cardiac safety assessment.
